SCHEMBL21921037

SCHEMBL21921037

CCOC(=O)c1nc(-c2cccc(Cl)c2Cl)c(C)nc1N1CCC2(CC1)Cc1ccccc1[C@H]2N

nearest known ligand 0.60

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PTPN11 Q06124 20/20 0.60
KCNH2 Q12809 3/20 0.53
EGFR P00533 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23024349 1.00 PTPN11 (0.60) PTPN11KCNH2EGFR
SCHEMBL29550546 1.00 PTPN11 (0.60) PTPN11KCNH2EGFR
SCHEMBL30683768 1.00 PTPN11 (0.60) PTPN11KCNH2EGFR
SCHEMBL30683780 0.90 PTPN11 (0.52) PTPN11KCNH2EGFR
SCHEMBL22789616 0.90 PTPN11 (0.52) PTPN11KCNH2EGFR
SCHEMBL29550651 0.90 PTPN11 (0.52) PTPN11KCNH2EGFR
SCHEMBL30683776 0.90 PTPN11 (0.52) PTPN11KCNH2EGFR
SCHEMBL21921220 0.90 PTPN11 (0.64) PTPN11KCNH2EGFR
SCHEMBL24704103 0.90 PTPN11 (0.71) PTPN11KCNH2EGFR
SCHEMBL21921223 0.90 PTPN11 (0.71) PTPN11KCNH2EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220388977-A1 SHP2 PHOSPHATASE ALLOSTERIC INHIBITOR BEIJING SHENOGEN PHARMA GROUP LTD. (CN) 2022-12-08 US disclosed
US-20210393623-A1 Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors JACOBIO PHARMACEUTICALS CO LTD (CN) 2021-12-23 US disclosed
US-20210355105-A1 REGULATOR OF NITROGEN-CONTAINING HETEROAROMATIC DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2021-11-18 US disclosed
WO-2020249079-A1 SHP2 PHOSPHATASE ALLOSTERIC INHIBITOR 北京盛诺基医药科技股份有限公司 2020-12-17 WO disclosed
WO-2020063760-A1 NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2020-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210355105-A1 REGULATOR OF NITROGEN-CONTAINING HETEROAROMATIC DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF PTPN11, PTPN1, PTPN7 PTPN11 1/4885KCNH2 4613/4885EGFR 1050/4885
US-20220388977-A1 SHP2 PHOSPHATASE ALLOSTERIC INHIBITOR PTPN1, PTPN5, PTPN18 PTPN11 10/4885KCNH2 3331/4885EGFR 738/4885
US-20210393623-A1 Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors PTPN1, PTPN5, PTPN2 PTPN11 10/4885KCNH2 4388/4885EGFR 629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.